Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma

Nozomi Niitsu, Masataka Okamoto, Hirokazu Nakamine, Masami Hirano

研究成果: Article査読

18 被引用数 (Scopus)

抄録

We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.

本文言語English
ページ(範囲)1837-1841
ページ数5
ジャーナルLeukemia Research
32
12
DOI
出版ステータスPublished - 12-2008
外部発表はい

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

フィンガープリント 「Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル